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The current interest in malaria elimination has led to a renewed interest in drugs that can be used for mass
administration to minimize malaria transmission. Primaquine (PQ) is the only generally available drug with
a strong activity against mature Plasmodium falciparum gametocytes, the parasite stage responsible for trans-
mission. Despite concerns about PQ-induced hemolysis in glucose-6-phosphate dehydrogenase (G6PD)-defi-
cient individuals, a single dose of PQ may be safe and efficacious in clearing gametocytes that persist after
conventional treatment. As part of a mass drug intervention, we determined the hemolytic effect of sulfadoxine-
pyrimethamine (SP) plus artesunate (AS) plus a single dose of primaquine (PQ; 0.75 mg/kg of body weight) in
children aged 1 to 12 years. Children were randomized to receive SPASPQ or placebo; those with a
hemoglobin (Hb) level below 8 g/dl were excluded from receiving PQ and received SPAS. The Hb concen-
tration was significantly reduced 7 days after SPASPQ treatment but not after placebo or SPAS treat-
ment. This reduction in Hb was most pronounced in G6PD-deficient (G6PD A) individuals (2.5 g/dl; 95%
confidence interval [95% CI], 1.2 to 3.8 g/dl) but was also observed in heterozygotes (G6PD A) (1.6 g/dl;
95% CI, 0.9 to 2.2 g/dl) and individuals with the wild-type genotype (G6PD B) (0.5 g/dl; 95% CI, 0.4 to
0.6 g/dl). Moderate anemia (Hb level of <8 g/dl) was observed in 40% (6/15 individuals) of the G6PD A,
11.1% (3/27 individuals) of the G6PD A, and 4.5% (18/399 individuals) of the G6PD B individuals; one case of
severe anemia (Hb level of <5 g/dl) was observed. PQ may cause moderate anemia when coadministered with
artemisinins, and excluding individuals based on G6PD status alone may not be sufficient to prevent PQ-
induced hemolysis.
Primaquine (PQ) is receiving renewed attention in light of
its potential role in malaria elimination strategies (22, 45, 49).
Malaria elimination is back on the agenda after recent reports
of substantial reductions in Plasmodium falciparum malaria
transmission intensity throughout the African continent (5, 8,
14, 31). Wide-scale implementation of artemisinin-based com-
bination therapy (ACT) has had a beneficial effect on the
burden of malaria in several areas (5, 8), through its high cure
rates (1, 9, 39, 41) and activity against sexual-stage parasites
that ensure malaria transmission (9, 39, 41). However, the
effect of ACT against sexual-stage parasites is probably largely
restricted to immature gametocytes (33), and mature infec-
tious gametocytes may persist for several weeks after ACT
treatment (9, 37). As a consequence, ACT reduces but does
not prevent posttreatment malaria transmission (9, 39, 41).
The addition of a more efficacious gametocytocidal drug may
be of value in situations where antimalarial drugs are em-
ployed for control programs that specifically aim to reduce or
eliminate malaria transmission and where the force of trans-
mission is sufficiently great that ACT in combination with vec-
tor control measures will not lead to elimination.
PQ is an 8-aminoquinolone that is widely used for the rad-
ical treatment of the liver hypnozoites of Plasmodium vivax
parasites (26, 42). It also actively clears mature P. falciparum
gametocytes (12, 37, 44). PQ has been suggested to be of added
value to ACT in clearing P. falciparum gametocytes (37, 44, 45,
49) and was previously recommended as a useful addition to
schizontocidal drugs to reduce malaria transmission (47, 49). A
recently published mathematical model suggests that interven-
tions with an antimalarial drug combination containing PQ
may result in the interruption of malaria transmission (25). PQ
may therefore also be a valuable component of mass drug
interventions that aim to eliminate malaria. One major con-
cern that complicates wide-scale use of PQ is its potential
hemolytic side effect (37, 42, 45, 47). This hemolytic effect may
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be most pronounced in individuals receiving PQ in high doses
(3, 42) or over several days (3, 17), and clinically important
hemolysis is generally thought to be restricted to individuals
who are glucose-6-phosphate dehydrogenase (G6PD) deficient
(17, 42, 45, 47), which is a common genetic variant in areas
where malaria is endemic (35). However, even a single dose of
PQ (0.75 mg/kg of body weight; 45 mg for adults) may result in
a transient reduction in hemoglobin levels (37), or possibly in
severe anemia (32, 34). If clinically significant hemolysis with
single-dose PQ is restricted to G6PD-deficient individuals and
near-patient phenotypic G6PD testing becomes feasible (40), it
will potentially be possible to test and exclude G6PD-deficient
individuals in mass drug interventions. If mass drug interven-
tions combine ACT with PQ, it is important to acknowledge
the possibility that artemisinins could potentiate the hemolytic
effects of PQ. This may have been the basis for the significant
hemolysis seen with the (now-withdrawn) chlorproguanil-dap-
sone (CD)-plus-artesunate (AS) combination (21). Here we
describe a study undertaken as part of a large-scale mass drug
intervention with sulfadoxine-pyrimethamine plus artesunate
followed by a single dose of PQ (SPASPQ). Since hemo-
lysis is the major practical limitation of PQ, we studied the
impact of the drug combination on hemoglobin concentrations
in relation to G6PD deficiency and other factors that may be
associated with drug-induced hemolysis.
MATERIALS AND METHODS
This study was conducted in February and March 2008 as part of a large mass
drug administration study in the area of Lower Moshi, northern Tanzania (lat-
itude, 3°61 to 3°68S; longitude, 37°32 to 37°38E). Malaria transmission in this
area is low, with an estimated entomologic inoculation rate (EIR) of 3.4 (95%
confidence interval [95% CI], 0.7 to 9.9) infectious bites per person per year in
2004 (30). Transmission in the area is largely restricted to the long rainy season
(May to July) and an unpredictable short rainy season (October to November).
In a cross-sectional survey that preceded the mass drug administration, a micro-
scopic P. falciparum parasite prevalence of 0.62% (95% CI, 0.13 to 1.8%) was
detected.
Intervention. In the mass drug intervention, 16 geographically defined clusters
of households were randomized at a ratio of 1:1 to receive either placebo (once
daily over 3 days) or a gametocytocidal drug combination that consisted of (i)
sulfadoxine-pyrimethamine (25 mg sulfadoxine plus 1.25 mg/kg as a single dose
on the first day; Fansidar, Roche, Switzerland), (ii) artesunate (AS) (4 mg/kg/day
for 3 days; Arsumax, Sanofi, France), and (iii) primaquine (0.75 mg/kg as a single
dose on the third day of treatment, in conjunction with the last dose of AS;
Tiofarma BV, Netherlands) (37). Children of less than 1 year of age were
excluded from the intervention. A total of 2,437 individuals received placebo
(951 of whom were 12 years of age), and 2,164 received gametocytocidal drugs
(926 of whom 12 years of age). PQ was produced as 7.5- and 15-mg tablets
following the regulations of the European Pharmacopeia and were tested for
content and stability. Treatment was given regardless of the presence of para-
sites, and treatment was observed directly by field workers. If vomiting occurred
within 20 min, a replacement dose was administered. In case of repeated vom-
iting, the child was excluded. Dosing was based on age because weighing indi-
viduals was considered unfeasible under field conditions, where rapid adminis-
tration of drugs relied on small teams visiting individual households. Treatment
teams consisted of one clinically qualified person (clinician, nurse, or health
officer) and one or two fieldworkers. The weight-age relationship was determined
based on data from two cross-sectional studies that were conducted in 2005 and
included a total of 2,752 inhabitants (38). Drugs were administered as described
in Table 1. Individual written consent was obtained from all literate adults; an
independent literate adult witness gave consent for illiterate adults. Parents/
caretakers gave consent for their children. Ethical approval was given by the
ethical board of the Tanzanian National Institute of Medical Research (NIMR/
HQ/R.8a/Vol. IX/491) and the Tanzanian Food and Drug Authority (CE.57/180/
01/8). The protocol for the mass drug administration study was registered online
at Clinical Trials.gov (http://clinicaltrials.gov/ct2/show/NCT00509015).
Safety. The hemoglobin (Hb) concentration was determined by use of a
HemoCue photometer (Angelholm, Sweden) for all children of 12 years of age
randomized to receive SPASPQ and for a random sample of children ran-
domized to receive placebo. The HemoCue 201 system has an internal elec-
tronic self test which automatically verifies the calibration of the instrument each
time the analyzer is switched on and every second hour thereafter. The impre-
cision in Hb measurements was previously determined to be 0.75%, and the
correlation coefficient with the ICSH international reference method was 0.99
(4). Individuals with an Hb level below 5 g/dl were excluded from the interven-
tion and transported to the nearby Kilimanjaro Christian Medical Centre
(KCMC) for blood transfusion and adequate clinical care. Those with an Hb
level below 8 g/dl were excluded from PQ treatment, received only SPAS, and
were given hematinic drugs (ferrous sulfate and folic acid). This meant that of
the 926 children of 12 years of age who were initially considered eligible for
SPASPQ, 37 were excluded from PQ treatment because of an Hb level of 8
g/dl and instead received SPAS.
Sampling and follow-up. The hematolytic effect of the drug combination was
evaluated in a selection of children under 12 years of age who provided an
additional day 7 finger-prick sample for Hb measurement and a filter paper DNA
sample. The selection for this follow-up sampling was done prior to treatment
and at the household level. Selected households were visited by a study team with
a list of all individuals who had received treatment. All treated children were
asked to donate a finger-prick blood sample, regardless of symptoms suggestive
of anemia. Day 7 after initiation of treatment was chosen because hemolysis may
last for 7 days after PQ treatment (23), and we previously observed that the
reduction in hemoglobin concentration was most pronounced on day 7 (37).
Because of the transient nature of PQ-induced reductions in hemoglobin con-
centration (37), individuals were not routinely followed up afterwards but were
seen during the evaluation phase of the mass drug intervention, which continued
for 5 months postintervention.
Sample size considerations. The sample size for hemoglobin measurements
was based on an estimated prevalence of G6PD A individuals of 4% and of
G6PD A individuals of 10% in the study area (36) and an expected proportion
of 50% of the individuals with the G6PD A genotype and 5% of the individuals
with the G6PD B genotype experiencing hemolysis after treatment, defined as a
reduction in Hb level of at least 20% compared to baseline values (37). Based on
these assumptions, enrolling 500 individuals who were treated with SPASPQ
would result in an estimated 20 individuals with the G6PD A genotype, 50 with
the G6PD A genotype, and 430 with the G6PD B wild-type genotype, giving
sufficient power to detect the expected difference between the G6PD A and
G6PD B groups (Z  1.96; Z	  0.84). To allow comparison with the placebo
group, where no hemolysis was expected, we aimed at including 100 placebo-
treated individuals. No formal randomization was done to include children in this
ancillary study. A team of field workers visited the largest feasible number of
randomly selected households for day 7 sampling without prior selection of
individuals.
DNA extraction and genotyping. DNA was extracted from filter paper by use
of a Chelex 100-based method. G6PD deficiency was determined by screening
human DNA for single nucleotide polymorphisms in the G6PD gene (G202A
and A376G) by a simple high-throughput method using PCR, sequence-specific
oligonucleotide probes (SSOPs), and enzyme-linked immunosorbent assay
(ELISA)-based technology (20). Primers described by Mombo et al. (28) were
used to amplify a 919-bp fragment of the G6PD gene covering the mutation site
TABLE 1. Dosing scheme for intervention with sulfadoxime-
pyrimethamine plus artesunate plus primaquinea
Age (yr) Weight (kg)(IQR)b
Gametocytocidal drug combination
Sulfadoxine (mg)/
pyrimethamine (mg)
Artesunate
(mg)
Primaquine
(mg)
1–2 11.0 (9.5–11.6) 250/12.5 25 7.5
3–4 12.9 (11.5–14.5) 500/25 50 15
5–7 16.7 (14.8–19.0) 500/25 75 15
8–11 23.0 (20.5–27.1) 750/37.5 100 22.5
a All individuals receiving placebo were given a dose of 1 tablet. Sulfadoxine-
pyrimethamine and artesunate were administered at the nearest half tablet, and
primaquine was administered as a combination of 7.5-mg and 15-mg tablets.
b IQR, interquartile range (25th to 75th percentiles). The weights of different
age groups were determined using previously published cross-sectional surveys of
2,752 inhabitants of the study population.
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at codon 68. Individuals with no G202A mutation were classified as having the
G6PD B genotype, heterozygotes for the G202A mutation were classified as
having the G6PD A genotype, and homozygotes or hemizygotes (males) for the
G202A mutation were classified as having the G6PD A genotype. The preva-
lence of -thalassemia was determined by detection of the African -globin
deletion, 3.7, by PCR as described by Liu et al. (27). Glutathione S-trans-
ferase-
 (GSTM1) polymorphisms were determined by a multiplex PCR using
primers described by Bro¨ckmoller et al. (11). Beta-globin primers were included
in the reaction mixture as an internal positive control. A 650-bp PCR product
was expected for GSTM1, and the absence of this fragment indicated 2 null
alleles (GSTM1-null). Sickle cell status was not determined in this study because
of a low prevalence of this hemoglobinopathy in the study area. The mean
prevalence of the HbAS genotype in the Kilimanjaro region was previously
estimated to be 2.1% (21/990 individuals), and that of the HbSS genotype was
estimated to be 0% (19; A. Manjurano et al., unpublished data). A pilot study in
the study area confirmed this low prevalence (M. Daou et al., unpublished data).
Statistical analyses. Data were double entered and imported into STATA 10.0
(Statacorp, TX) for statistical analysis. Hemoglobin concentrations were nor-
mally distributed, and values before and after treatment were compared by a
paired-sample t test; values between treatment groups were compared by analysis
of variance (ANOVA). The change in hemoglobin concentration after treatment
was expressed as a percentage of the enrolment value. To determine a possible
influence of relative overdosing, a variable was created that indicated whether
children were in the lowest year of their age category (i.e., being a 1-year-old in
the 1- to 2-year-old age group, a 3-year-old in the 3- to 4-year-old age group,
etc.). Multivariate linear regression models were used to determine whether
relative overdosing was independently associated with a change in Hb level.
Factors with a P value of 0.1 in univariate models were included in a multi-
variate model and retained if the P value was 0.05 in the multivariate model.
Multivariate regression models were also used to adjust the association between
G6PD status and the change in Hb level for relative overdosing.
RESULTS
Baseline screening revealed six children with severe anemia
(0.5% [6/1,106 children]) and 73 children with moderate ane-
mia (7.1% [78/1,106 children]). Fourteen children vomited af-
ter receiving SPASPQ, compared to 5 in the placebo arm
and 0 in the SPAS arm. Vomiting did not lead to exclusion
from the study; no repeated vomiting occurred. A total of 734
children from 375 households were selected and asked to do-
nate a second blood sample. Of these, 3.7% (22/587 children)
refused in the SPASPQ arm, 8.0% in the SPAS arm (2/25
children), and 4.9% (6/122 children) in the placebo arm. As a
result, combined day 0 and day 7 Hb measurements were
available for 565 children who received SPASPQ, 116 chil-
dren who received placebo, and 23 children who received
SPAS. Baseline values and changes in Hb concentration after
the intervention are presented in Table 2. In the placebo
group, there was no change in Hb concentration 7 days after
the intervention (mean difference, 0.05 g/dl [95% CI, 0.28
to 0.18 g/dl]; P  0.65), and none of the children developed
moderate or severe anemia in the week after administration of
the placebo. In the group of individuals treated with
SPASPQ, there was a statistically significant reduction in
Hb concentration on day 7 relative to that on day 0 (mean
difference, 0.58 g/dl [95% CI, 0.46 to 0.71 g/dl]; P 
0.0001). In this group of children, all of whom had a baseline
Hb concentration of 8 g/dl, one 5-year-old child developed
severe anemia, with an Hb level of 4.8 g/dl compared with a
baseline of 8.3 g/dl. This child was given hematinic drugs and
recovered without the need for additional treatment (Hb con-
centration, 7.8 g/dl 2 weeks after initiation of the intervention
and 12.3 g/dl 3 months after intervention). Children who de-
veloped moderate anemia were given hematinic drugs and
were observed in the follow-up period, which continued for 5
months after the intervention. In a small group (n  23) of
individuals who were excluded from PQ treatment because
their baseline Hb concentration was below 8 g/dl, we observed
a statistically significant increase in Hb concentration between
enrolment and day 7 after the initiation of treatment (mean
difference, 0.62 g/dl [95% CI, 0.10 to 1.13 g/dl]; P 
0.02).
Factors related to drug-induced hemolysis. DNA samples
were available for 562 children. The frequencies of G6PD
deficiency were 8.4% (G6PD A heterozygotes; 95% CI, 6.1 to
10.7%) and 3.9% (G6PD A homo-/hemizygotes; 95% CI, 2.3
to 5.5%). The prevalences of -thalassemia were 25.2%
(/ heterozygotes; 95% CI, 21.2 to 29.2%) and 2.4%
(/ homozygotes; 95% CI, 1.0 to 3.8%). The prevalence
of the GSTM1 null genotype was 29.1% (95% CI, 25.2 to
32.9%). The change in Hb concentration in the intervention
group was related to G6PD deficiency status (P  0.0001),
although a statistically significant reduction in Hb concentra-
tion was observed for all genotypes (Fig. 1). The mean change
TABLE 2. Baseline values and changes in Hb concentration in children who received placebo, SPASPQ, or SPAS
Parameter Placebo group SPASPQ group SPAS group
n 116 564 23
Age (yr) (median IQR) 4 (2–6.5) 5 (3–8) 3 (2–4)
Gender (% male no. of males/total no. of individuals) 47.4 (55/116) 54.8 (309/564) 56.5 (13/23)
Hb concn at enrolment (g/dl) (median IQR) 11.3 (9.9–12.3) 11.7 (10.4–12.8) 6.7 (6.2–7.3)
Mean difference in Hb concn on day 7 vs that on day 0
(g/dl) (95% CI)
0.05 (0.28–0.18) 0.58 (0.46–0.71)a 0.62 (0.10–1.13)b
a P  0.0001.
b P  0.02.
FIG. 1. Hb concentration on day 7 after treatment with SPASPQ,
shown as a percentage of the baseline value in relation to G6PD genotype.
There was a significant reduction in Hb concentration in G6PD B (P 
0.0001), G6PD A (P 0.0001), and G6PD A (P 0.001) individuals on
day 7 after treatment compared to that on day 0 (d0).
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in Hb concentration compared to baseline values was 0.5 g/dl
(95% CI, 0.4 to 0.6 g/dl) for children with the wild-type
G6PD B genotype. The reduction in Hb concentration was
significantly more pronounced in heterozygotes (G6PD A)
(mean change, 1.6 g/dl [95% CI, 0.9 to 2.2 g/dl] com-
pared to G6PD B group; P  0.001) and in homozygote defi-
cient children (G6PD A) (mean change, 2.5 g/dl [95% CI,
1.2 to 3.8 g/dl] compared to G6PD B group; P 0.001). Hb
concentrations before and after treatment in individuals who
developed moderate or severe anemia are shown in Fig. 2.
Although the categorization has the disadvantage of classifying
some minimal reductions in Hb as “development of moderate
anemia” (Fig. 2, first observation), it illustrates reductions with
potential clinical relevance. While all children had an Hb level
of 8 g/dl prior to the intervention, 4.5% (18/399 children) of
the G6PD B children became moderately anemic (Hb 8 g/dl)
after the intervention. For G6PD A and G6PD A children,
this proportion was 11.1% (3/27 children) and 40.0% (6/15
children), respectively. Compared to children with the G6PD B
genotype, the relative risk of becoming moderately anemic
after the intervention was 2.46 (95% CI, 0.77 to 7.84) for
G6PD A children and 8.87 (95% CI, 4.12 to 19.09) for G6PD
A children. Despite the lower occurrence of moderate ane-
mia in children with the G6PD A or G6PD B genotype, some
children in each category experienced a considerable reduction
in Hb concentration. The absolute number of children who
became moderately anemic after the intervention was largest
for children with the G6PD B genotype (Fig. 2). The previously
mentioned child who developed severe anemia after the inter-
vention had the G6PD A genotype. Hemolysis was not related
to -thalassemia (P  0.40) (Fig. 3A) or the GSTM1 poly-
morphism (P  0.22) (Fig. 3B) and was not more common in
G6PD B males than in G6PD B females (P  0.23). In the
placebo group, there was no relationship between a change in
Hb concentration and any of the genetic polymorphisms stud-
ied (data not shown).
Dosing based on age group creates the risk of giving children
in the lower part of their age group a relatively high dose of
drugs. This was examined by determining whether being in the
lowest year of the age group was associated with a reduction in
Hb concentration relative to that at enrolment. In children
below 5 years of age, those who were in the lowest year of their
age group had significant reductions in Hb levels that were
independent of G6PD genotype or other genetic polymor-
phisms (Table 3). For older age groups, this increased risk of
overdosing was not observed (P  0.93), while the effect of
G6PD deficiency was still apparent (Table 3).
DISCUSSION
In this study, we observed a statistically significant reduction
in Hb concentration in children after administration of a
gametocytocidal drug combination containing PQ and an ar-
temisinin. The observed hemolysis was strongly related to
G6PD deficiency but was not restricted to individuals with the
G6PD A or A genotype. In the study area, with a moderate
prevalence of the African-variant G6PD deficiency, the major-
ity of children who developed moderate anemia were wild type
at the G6PD A allele. More than five percent of the children
became moderately anemic after administration of the PQ
combination. This is potentially important for mass drug ad-
ministration both as part of attempts to eliminate falciparum
FIG. 2. Hb concentrations before and after SPASPQ treatment
for those individuals who became moderately anemic (Hb level of 8
g/dl) after the intervention. On the x axis is the hemoglobin concen-
tration in g/dl; on the y axis are individual observations for G6PD
homo-/hemizygous individuals (6 of 15 individuals treated [40%] be-
came moderately anemic), heterozygotes (3 of 27 individuals [11.1%]),
and wild-type individuals (18 of 399 individuals [4.5%]). Arrows rep-
resent individual baseline (right) and postintervention (left) hemoglo-
bin measurements. Dashed lines represent the values below which
individuals are considered to have severe (5 g/dl) or moderate (8 g/dl)
anemia.
FIG. 3. Hb concentration on day 7 after treatment with SPASPQ,
shown as a percentage of the baseline value in relation to -thalassemia
genotype (A) or GSTM1 genotype (B). The reduction in Hb concentra-
tion was not related to -thalassemia genotype (P  0.23) or GSTM1
genotype (P  0.50).
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malaria and in areas where vivax malaria is predominant,
where coadministration of ACTs with PQ is increasingly likely
(18).
This study provides evidence for reductions in Hb concen-
trations after a single dose of PQ, at least in the context of
coadministration with SPAS. Because the prevalence of the
G6PD A genotype was low in the current study population
(4%) (36), because hemolysis in individuals with African-
variant G6PD deficiency is generally milder than that in indi-
viduals with the Mediterranean variant (6), and because we
excluded all children with moderate anemia, we did not expect
any clinically relevant hemolysis in the current study. In con-
trast to our expectations, we observed considerable and statis-
tically significant reductions in Hb concentrations, and 5% of
the children became moderately anemic after the intervention
with SPASPQ. This reduction in Hb appeared transient
(37), and none of the children needed hospitalization or expe-
rienced clinical consequences from the intervention in terms of
clinical symptoms of anemia or life-threatening anemia. The
asymptomatic nature of hemolysis is in line with previous stud-
ies where eight adult African-Americans with the G6PD A
variant developed mild, asymptomatic hemolysis (decrease in
Hb of 0.5 to 2.5 g/dl) after weekly administration of 45 mg PQ
for 8 weeks (10) and where 8 to 18% of the red cells of
G6PD-deficient Thai adults were affected after a single dose of
45 mg PQ (15). This study was not designed to determine the
hemolytic effect of PQ compared to antimalarial treatment
without PQ. A reduction in Hb as a consequence of SPAS
treatment can therefore not be excluded (29). However, in line
with our previous observations (37), we observed no hemolysis,
but an increase in Hb concentration, in the small group of
children who received only SPAS. While this observation
could be due partly to regression to the mean in individuals
who had low baseline values (Hb  8 g/dl), the increase was
considerable and we found no indications for drug-induced
hemolysis in either G6PD wild-type or three G6PD heterozy-
gote individuals in this treatment arm. We therefore consider
it plausible that the observed hemolysis was PQ induced. The
combined treatment of PQ with artemisinins may have resulted
in a more pronounced hemolytic effect of PQ, as was suggested
for chlorproguanil-dapsone (CD). CD has a hemolytic effect
when administered alone (2), and this effect may be more
pronounced when CD is coadministered with AS (21), al-
though another study suggested that the safety profile of CD
was not influenced by coadministration with different doses of
AS (46). Based on the current data, we therefore cannot ex-
clude a potentiating effect of AS on the hematolytic effect of
PQ; this would have required a study arm without AS.
The severity of hemolysis was highly variable between indi-
viduals and strongly related with G6PD genotype, being most
pronounced in homo-/hemizygous (G6PD A) individuals,
less pronounced in heterozygotes (G6PD A), and least pro-
nounced in individuals with the wild-type genotype (G6PD B).
Even in G6PD B individuals, we observed a statistically signif-
icant reduction in Hb concentration after SPASPQ treat-
ment. Three percent of G6PD B children experienced a reduc-
tion in Hb of 3 g/dl (12/399 children), and 4.5% became
moderately anemic. We hypothesized that other genetic fac-
tors would explain part of this hemolysis, but we observed no
association with -thalassemia or the examined polymor-
phism in GSTM1, which is involved in protection against oxi-
dative stress and has been implicated in various types of ane-
mia (16). Relative overdosing was related to the degree of
hemolysis in children below 5 years of age. This indicates that
future studies should base treatment dose on weight rather
than age and highlights a shortcoming of our approach. How-
ever, this apparent overdosing could not explain the hemolysis
we observed in the G6PD B group. Our findings therefore
suggest that other (genetic) factors play a role in PQ-induced
hemolysis or that some G6PD-deficient individuals were not
detected by our PCR-based screening. Direct measurement of
enzyme activity, i.e., the NADPH production capacity of
G6PD, can be used for diagnosis of all mutations associated
with G6PD deficiency, while PCR determines only one muta-
tion per set of primers. At present, 140 mutations are known in
the corresponding DNA (7), and we screened only for one of
the most prevalent mutations, G6PD A. Although the G6PD
A genotype accounts for 90% of G6PD deficiency in Africa
(13), it is possible that G6PD deficiency due to mutations other
than G6PD A explains part of the observed hemolysis. A
recent study in Uganda reported that 30% of males who were
enzymatically G6PD deficient were wild type for the G6PD
A allele (24). Although we found no evidence for an excess
in G6PD A allele-unrelated hemolysis in males, this finding
TABLE 3. Impact of G6PD status and being in the lower part of an age group on relative Hb level in children
Patient group and genotype or portion of
age group
Proportion (no. of
children/total no.
in group)
Coefficient 	 (95% CI) P value
Children under 5 years of age
G6PD genotype
Wild type (B) 87.7 (222/253) Reference
Heterozygote (A) 7.9 (20/253) 6.90 (15.37–1.58) 0.11
Homozygote (A) 4.3 (11/253) 14.64 (24.84–4.43) 0.005
Portion of age group
Not in lowest year of age group 53.8 (136/253) Reference
In lowest year of age group 46.2 (117/253) 4.41 (8.58–0.23) 0.04
Children aged 5 to 11 years
G6PD genotype
Wild type (B) 91.1 (234/257) Reference
Heterozygote (A) 6.2 (16/257) 12.22 (17.81–6.64) 0.001
Homozygote (A) 2.7 (7/257) 21.40 (29.45–13.35) 0.001
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indicates shortcomings of the PCR-based method to determine
G6PD deficiency. Our study had several other shortcomings.
Parasite carriage in the children was not determined prior to
the intervention. A cross-sectional study of a selection of the
population indicated a preintervention parasite prevalence of
0.6% by microscopy (S. A. Shekalaghe et al., unpublished
data), making malaria-induced hemolysis a very unlikely expla-
nation for hemolysis after the intervention. In addition, chil-
dren were not routinely followed up after day 7 postinterven-
tion, and as a result, we have no detailed hematological data
beyond this time point for all children, although we previously
reported complete hematological recovery between day 7 and
day 14 (37). The current data are not conclusive and are in-
sufficient to lead to public health policy changes. The value of
PQ in malaria transmission-reducing strategies depends on the
individual risks in relation to the individual and community
benefits, which both depend on the transmission setting. Sub-
stantial community benefits in terms of a reduction in the
burden of malaria may justify side effects even if the immediate
individual benefit is limited. In the current study, the immedi-
ate individual benefits of drug administration were negligible:
only 0.6% of the individuals enrolled in the mass drug inter-
vention were parasitemic. The community effects will be de-
scribed in detail elsewhere (Shekalaghe et al., unpublished
data); the current study describes solely the potential risk for
the individual.
Together with a recently published study (37), our data sug-
gest that PQ at the current dosing schedule may not be optimal
for wide-scale implementation in combination with artemisi-
nins, even in areas with a relatively low prevalence of G6PD
deficiency. PCR-based screening for G6PD deficiency would
not have been sufficient to prevent hemolysis in our study
population, where 5% of the G6PD B children became mod-
erately anemic after PQ. The importance of hematolytic side
effects of antimalarial drugs was recently shown for CD, which
was withdrawn from the market after hematological adverse
effects in trial participants (48). Because of the potential role
of PQ in combination with artemisinins in malaria elimination
efforts (22, 25, 45, 49), we consider it important to conduct
dose-finding studies to define a dosage of PQ that has game-
tocytocidal properties that are similar to those of PQ at 0.75
mg/kg (37) but is sufficiently low to prevent hemolytic side
effects. Alternatively, gametocytocidal drugs with lower hema-
totoxicity, including the 8-aminoquinoline bulaquine (43),
could be considered for malaria transmission-reducing inter-
ventions.
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